In this context, the targeting of cellular proteins that function downstream of FLT3 (e.g., CDK9), which mediate the transcription of critical survival proteins (e.g., MCL-1) relevant to AML, might be a promising therapeutic strategy against the emerging resistance [22,24]. Here, MCL1 is linked to acute myeloid leukemia.